Inventory

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Inventory

Inventory

Inventory consisted of the following (in thousands):

	September 30,		December 31,
	2023		2022
Raw materials	$	4,060	$	—
Work-in-process	15,046		2,994
Finished goods	1,050		26
Total inventory	$	20,156	$	3,020

The Company’s capitalized inventory consists of costs incurred subsequent to FDA approval of KRAZATI in December 2022. There were no inventory write downs during the three and nine months ended September 30, 2023.